Literature DB >> 1705191

Elution of vancomycin, daptomycin, and amikacin from acrylic bone cement.

D K Kuechle1, G C Landon, D M Musher, P C Noble.   

Abstract

Increasing antibiotic resistance of bacteria that infect prosthetic joints has stimulated interest in the incorporation of more effective antimicrobial agents into polymethylmethacrylate (PMMA). Vancomycin and daptomycin are effective against nearly all staphylococci and streptococci, and amikacin has a broader spectrum against gram-negative bacilli than do other aminoglycosides such as gentamicin. These three antibiotics maintained bioactivity after incorporation into several commonly used preparations of PMMA and eluted readily into the surrounding medium. Preparing PMMA under negative atmospheric pressure, which decreases porosity, caused a 50% reduction in antibiotic release; the addition of 25% dextran, which increases porosity, greatly facilitated elution of these antibiotics. Based on their broad antibacterial effect against gram-positive and gram-negative bacteria, inclusion of vancomycin and amikacin in PMMA merits clinical study. The addition of these antibiotics to PMMA, together with dextran, may be applicable when structural integrity is unimportant but a substantial local antimicrobial effect is desired, such as in the use of antibiotic-containing beads to treat osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705191

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  43 in total

1.  In vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus.

Authors:  Yuhan Chang; Wen-Chien Chen; Pang-Hsin Hsieh; Dave W Chen; Mel S Lee; Hsin-Nung Shih; Steve W N Ueng
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Treatment Options for Orthopedic Device-related Infections.

Authors:  Edna Toubes; John Segreti
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

3.  Strength of antimicrobial bone cement decreases with increased poragen fraction.

Authors:  Matt Nugent; Alex McLaren; Brent Vernon; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

4.  Mixing method affects elution and strength of high-dose ALBC: a pilot study.

Authors:  Ryan Miller; Alex McLaren; Christine Leon; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

5.  Chitosan sponges to locally deliver amikacin and vancomycin: a pilot in vitro evaluation.

Authors:  Scott P Noel; Harry S Courtney; Joel D Bumgardner; Warren O Haggard
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

6.  Effect of pulsed ultrasound in combination with gentamicin on bacterial viability in biofilms on bone cements in vivo.

Authors:  G T Ensing; B L Roeder; J L Nelson; J R van Horn; H C van der Mei; H J Busscher; W G Pitt
Journal:  J Appl Microbiol       Date:  2005       Impact factor: 3.772

7.  A daptomycin-xylitol-loaded polymethylmethacrylate bone cement: how much xylitol should be used?

Authors:  Ali Salehi; Ashley Cox Parker; Gladius Lewis; Harry S Courtney; Warren O Haggard
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

8.  Generic tobramycin elutes from bone cement faster than proprietary tobramycin.

Authors:  R L McLaren; A C McLaren; B L Vernon
Journal:  Clin Orthop Relat Res       Date:  2008-03-14       Impact factor: 4.176

Review 9.  Two-stage procedure in the treatment of late chronic hip infections--spacer implantation.

Authors:  Mohamed Sukeik; Fares S Haddad
Journal:  Int J Med Sci       Date:  2009-09-02       Impact factor: 3.738

10.  Treatment of proximal femur infections with antibiotic-loaded cement spacers.

Authors:  J Kelm; P Bohrer; E Schmitt; K Anagnostakos
Journal:  Int J Med Sci       Date:  2009-09-03       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.